rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Carl L. Gordon

Director and 10% owner

Company insider

Files Form 4 as: Director and 10% owner, Andrx Corp /de/; Director and 10% owner, Electra Therapeutics; Director, BlossomHill Therapeutics; Director, Scribe Therapeutics; Director and 10% owner, Compass Therapeutics; Director, Keros Therapeutics; Director and 10% owner, MBX Biosciences; Director, Lomond Therapeutics Holdings.

Every Form 4 they filed

In numbers

Trades disclosed
459
Buys
49
Sells
41
Bought
$299.6M
Sold
$140.5M
Companies
27
Companies where not an officer
27
First trade
17 May 2006
Last trade
28 Sep 2026
Last filed
30 Sep 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
Andrx Corp /de/Director, 10% owner · last 28 Sep 20261 buy · 0 sells
ETRA Electra TherapeuticsDirector, 10% owner · Biotechnology · last 21 Sep 20261 buy · 0 sells
BLSM BlossomHill TherapeuticsDirector · Biotechnology · last 10 Aug 20261 buy · 0 sells
SCTX Scribe TherapeuticsDirector · Biotechnology · last 27 Jul 20261 buy · 0 sells
CMPX Compass TherapeuticsDirector, 10% owner · Biotechnology · last 2 Jan 20269 buys · 1 sell
KROS Keros TherapeuticsDirector · Biotechnology · last 21 Nov 20251 buy · 1 sell
MBX MBX BiosciencesDirector, 10% owner · Biotechnology · last 18 Feb 20253 buys · 0 sells
Lomond Therapeutics HoldingsDirector · last 1 Nov 20240 buys · 0 sells
ACET Adicet BioDirector, 10% owner · Biotechnology · last 21 Aug 20242 buys · 0 sells
Terns PharmaceuticalsDirector, 10% owner · last 16 Jul 20243 buys · 2 sells
BiomX10% owner · Biotechnology · last 15 May 20240 buys · 1 sell
Kinnate BiopharmaDirector, 10% owner · last 3 Apr 20249 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
102Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/SEC FORM 4 Code C—10,690,530filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/SEC FORM 4 Bought$1.0M61,516 at $17.00filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/SEC FORM 4 Bought$10.0M588,235 at $17.00filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/option or derivativeSEC FORM 4 Code C—10,690,530 at $0.00filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/option or derivativeSEC FORM 4 Code C—2,000,962 at $0.00filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/option or derivativeSEC FORM 4 Code C—769,601 at $0.00filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/option or derivativeSEC FORM 4 Code C—564,187 at $0.00filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/option or derivativeSEC FORM 4 Code C—7,127,019 at $0.00filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/option or derivativeSEC FORM 4 Code C—1,333,975 at $0.00filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/option or derivativeSEC FORM 4 Code C—513,067 at $0.00filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/option or derivativeSEC FORM 4 Code C—256,448 at $0.00filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/SEC FORM 4 Code C—2,000,962filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/SEC FORM 4 Code C—769,601filing
28 Sep 2026filed 30 Sep 2026ADRX ADARx Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code C—10,690,530 at $0.00filing
28 Sep 2026filed 30 Sep 2026ADRX ADARx Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code C—2,000,962 at $0.00filing
28 Sep 2026filed 30 Sep 2026ADRX ADARx Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code C—769,601 at $0.00filing
28 Sep 2026filed 30 Sep 2026ADRX ADARx Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code C—564,187 at $0.00filing
28 Sep 2026filed 30 Sep 2026ADRX ADARx Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code C—7,127,019 at $0.00filing
28 Sep 2026filed 30 Sep 2026ADRX ADARx Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code C—1,333,975 at $0.00filing
28 Sep 2026filed 30 Sep 2026ADRX ADARx Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code C—513,067 at $0.00filing

Sectors

Health Care65
Not placed26

Buys in green, sells in red, by the company’s sector.

Related people

Neil LernerChief Accounting Officer · Chief Accounting Officer at Compass Therapeutics, filing Form 4 there in the last year
ORBIMED ADVISORS LLCDirector and 10% owner · Director and 10% owner at ADARx Pharmaceuticals, filing Form 4 there in the last year
Erez ChimovitsDirector · Director at ADARx Pharmaceuticals, filing Form 4 there in the last year
SR ONE CAPITAL MANAGEMENT, LLC10% owner · 10% owner at ADARx Pharmaceuticals, filing Form 4 there in the last year
LAV Biosciences Fund V, L.P.10% owner · 10% owner at ADARx Pharmaceuticals, filing Form 4 there in the last year
Dominic PiscitelliChief Financial Officer · Also traded ORIC in the last 90 days
Adam R. CraigExecutive Chairman · Also traded XFOR in the last 90 days
David KirskeChief Financial Officer · Also traded XFOR in the last 90 days